Massachusetts House Bill H4488

Massachusetts 2025-2026 Regular Session

• Introduced: 9/18/25
• Refer: 9/18/25

Caption

Relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth

Impact

By enforcing structured guidelines for how PBMs determine and adjust maximum allowable costs, Bill H4488 aims to level the playing field for pharmacies throughout the Commonwealth. Key provisions include mandatory responses to reimbursement challenges and specifying that pharmacies cannot be reimbursed less than what similar affiliates receive. This could lead to changes in the way PBMs operate and may improve the financial health of many local pharmacies, allowing them to serve communities more effectively. Additionally, the bill extends to PBMs working with state programs like MassHealth, reinforcing the importance of equitable practices in the public sector.

Summary

House Bill 4488 addresses the issue of reimbursements to pharmacies by pharmacy benefit managers (PBMs) in Massachusetts. The bill amends Chapter 176D of the General Laws to establish regulations regarding the setting of maximum allowable costs for prescription drugs, which are central to the reimbursement process for pharmacy services. Under the proposed legislation, PBMs are required to maintain an updated maximum allowable cost list and adhere to a set procedure when pharmacies challenge these costs. This aims to ensure that pharmacies are not reimbursed less than their acquisition costs for medications, thus safeguarding their financial viability and encouraging fair competition among pharmacy providers.

Contention

Notable points of contention in the discussions surrounding H4488 may include concerns related to the regulatory burden placed on PBMs and whether the requirements will lead to increased drug prices across the board. Critics argue that overly stringent regulations could force PBMs to raise costs, ultimately impacting consumers and healthcare plans negatively. Advocates for the bill, however, emphasize that these protections are necessary to prevent unfair pricing practices and to promote transparency in the pharmaceutical supply chain. The debate reflects broader tensions between maintaining affordable healthcare and ensuring fair business practices in the pharmacy sector.